MAP Pharmaceuticals, Inc. : Publications : Migraine

Migraine Manuscripts

Shrewsbury, S., Kori, S., Miller, D., Pedinoff, A. and Weinstein, S. "Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics" Curr Med Res Opin 2008; 24(7):1977-1985.
Shrewsbury, S., Cook, R., Taylor, G., Edwards, C., Ramadan, N. "Safety and Pharmacokinetics of Dihydroergotamine Mesylate Administered Via a Novel (TEMPO®) Inhaler" Headache 2008, 48:355-367.
Shrewsbury, S.B., Stonerook, M., Okikawa, J. K. "Intrapulmonary and intravenous administrations of DHE have similar CV effects in the conscious dog" Br J Pharmacol. PMID - 18289809 2008 May 26; 154(6):1254-1265.

Migraine Presentations

Utility of LEVADEX™ in Situations Where Early Intervention Paradigm is Impractical [186KB]
As presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS), June 2010
The Efficacy and Tolerability of LEVADEX™ (Orally Inhaled DHE) for the Treatment of Migraine in Subjects with Concomitant Asthma - A Subgroup Analysis [261KB]
As presented at the 52nd Annual Scientific Meeting of the American Headache Society (AHS), June 2010
Evaluation of Safety and Efficacy of MAP0004 in Treating Acute Menstrual Migraine [348KB]
As presented at the American Academy of Neurology (AAN) 62nd Annual Meeting, April 2010
Evaluation of Efficacy and Safety of LEVADEX™ in Treating Migraine with and without Allodynia and Reversing Allodynia, a Marker of Central Sensitization [161KB]
As presented at the American Academy of Neurology (AAN) 62nd Annual Meeting, April 2010
The Timing of Gastric Stasis in an Acute Migraine Attack and its Impact on Treatment [102KB]
As presented at the American Academy of Neurology (AAN) 62nd Annual Meeting, April 2010
Efficacy and tolerability of MAP0004, a novel inhaled therapy, in treating acute migraine [2.2MB]
As presented at the 14th Congress of the International Headache Society, September 2009
Efficacy evaluation of LEVADEX™ (previously MAP0004) in treating resistant migraine including migraine with allodynia, migraine treated late in its cycle, morning migraine and disabling migraine [695KB]
As presented at the 14th Congress of the International Headache Society, September 2009
Efficacy evaluation of LEVADEX™ (previously MAP0004) in treating a broad spectrum of acute migraine attacks including patients using triptans and patients not using triptans [2.1MB]
As presented at the 14th Congress of the International Headache Society, September 2009
Efficacy and Tolerability of MAP0004, Featuring a Novel Delivery System, In Treating Acute Migraine [105KB]
As presented at the European Headache and Migraine Trust International Congress (EHMTIC), September 2008
Precise Pulmonary Delivery of Dihydroergotamine and Mechanism for Reduced Adverse Effect Profile [246KB]
As presented at the European Headache and Migraine Trust International Congress (EHMTIC), September 2008
Sustained Pain Relief in Migraine is Not Necessarily Dependent on the PK of a Drug and Does Not Have to be at the Cost of Rapid Onset of Relief [74KB]
As presented at the European Headache and Migraine Trust International Congress (EHMTIC), September 2008
MAP0004, an Orally Inhaled Formulation of DHE, Delivers Faster and More Consistent Blood Levels of the Drug Compared to Traditional Oral, Subcutaneous, Intramuscular, and Intranasal Formulations of DHE [88KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
Pharmacological Profiling of Dihydroergotamine and its Relevance to Systemic Delivery via the Respiratory Tract [142KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
Newer Acute Migraine Specific Drugs May Provide Improved Sustained Relief and Freedom over 24 and 48 Hours Post Dosing [68KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
Systemic Pharmacokinetics of DHE When Delivered Via the Lung to Asthmatics by the Tempo® Inhaler [108KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
Assessment of QTc Effect of DHE When Delivered Via the Lung by the Tempo® Inhaler [79KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
Chronic Inhalation Toxicity Assessment of Dihydroergotamine in Dogs [142KB]
As presented at the American Headache Society (AHS) 50th Annual Headache Symposium, June 2008
Dihydroergotamine Mesylate Monohydrate Solid State Characterization for Inhalation Formulation: Polymorph Screening and Determination of Amorphous Content [362KB]
As presented at the Respiratory Drug Delivery Conference (RDD), May 2008
Precision Dosing of Dihydroergotamine (DHE) by Inhalation [603KB PDF]
As presented at the 13th Congress of the International Headache Society, June 2007
Rapid and Sustained Clinical Efficacy and Safety of Inhaled Dihydroergotamine Mesylate via a Novel Inhaler (Tempo® Inhaler) [1067KB PDF]
As presented at the American Headache Society (AHS) 49th Annual Headache Symposium, June 2007
Clinical Safety of Inhaled Dihydroergotamine Mesylate via a Novel System (Tempo® Inhaler) [3746KB PDF]
As presented at the American Headache Society (AHS) 49th Annual Headache Symposium, June 2007
Comparative Clinical Pharmacokinetics of Parent Drug and Metabolites Following Inhaled Dosing with Dihydroergotamine Mesylate via a Novel System (Tempo® Inhaler) [3937KB PDF]
As presented at the American Headache Society (AHS) 49th Annual Headache Symposium, June 2007
Delivery Performance of Dihydroergotamine Mesylate (DHE) Using the Breath Synchronized, Plume Controlled Tempo® Inhaler [455KB PDF]
As presented at the Respiratory Drug Delivery (RDD X) Conference, April 2006
Intra-pulmonary Artery as Compared to Peripheral Venous Dosing of Dihydroergotamine (DHE) in Telemeterized, Awake Dogs [219KB PDF]
As presented at the American Academy of Neurology (AAN) 58th Annual Meeting, April 2006